Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Next weeks update may well be an update on their 3/22 PR:
Additionally, the Company has entered negotiations with Pro Wave Ad Product ("PWA"), a Bulgarian Company, to supply the raw material for PWA's Contract in India for the production of a spray modulating the immune system under U.S. Patent No. 8,309,072 owned by Zhabilov Trust. This contract is valued at more than $50 million to PWA. This is the only approved use of this technology as a nutraceutical. The FDA issued a nutraceutical number to Harry Zhabilov on October 12, 2018. The first delivery under this agreement with PWA is expected to be in late spring 2021. The value to the Company is yet to be determined.
The spray product is a nutraceutical application, separate from the ITV-1 treatment that successfully completed Phase 3 clinical trials on August 7, 2014, with the Final Report being issued in November of 2016 by Assoc. Prof. Ivaylo Elenkov, MD, Chief researcher at the Specialized Hospital for Active Treatment of Infectious and Parasite Diseases. This report and the associated clinical trials were conducted under Bulgarian Drug Administration (BDA) guidelines. With Bulgaria joining the EMA in April of 2019, the BDA can no longer issue permits for mass use for the HIV/AIDS virus. Under the Company's new business arrangement with International Medical Partners, Ltd. (IMBL), new clinical trials are being planned and scheduled with Clinical Design, a Clinical Research Organization (CRO) in Bulgaria. The Company is finalizing negotiations with a Contract Manufacturer, also located in Bulgaria, for the production of the ITV-1 Immunotherapy treatment. The new clinical trials for the Patented and licensed ITV-1 treatment under the EMA guidelines will be submitted upon completion. When the EMA permit for mass use is issued, the Company plans to pursue Federal Drug Administration (FDA) approval under the Mutual Recognition Agreement between the FDA and EMA.
As a result of the necessity to perform Clinical trials under the EMA guidelines, the agreements with IMMB BG, which were in default, have been cancelled and superseded by the new agreements with IMBL and PAW.
Harry Zhabilov, CSO, stated, "With our new partners at IMBL, the CRO and the CMO, all located in Bulgaria, and all experienced in the EMA Permitting process, the next steps in bringing our Immunotherapy Treatment for HIV/AIDS and hepatitis C viruses to a point of approval by the EMA is on the right path. The contract being negotiated with PAW is expected to produce meaningful revenue generated from our technology."
Quarterly Report - Financial Statements March 31st is out just now on OTC website!
https://backend.otcmarkets.com/otcapi/company/financial-report/282626/content
Pretty good chance that next weeks deal is about this - from PR on 3/22:
Additionally, the Company has entered negotiations with Pro Wave Ad Product ("PWA"), a Bulgarian Company, to supply the raw material for PWA's Contract in India for the production of a spray modulating the immune system under U.S. Patent No. 8,309,072 owned by Zhabilov Trust. This contract is valued at more than $50 million to PWA. This is the only approved use of this technology as a nutraceutical. The FDA issued a nutraceutical number to Harry Zhabilov on October 12, 2018. The first delivery under this agreement with PWA is expected to be in late spring 2021. The value to the Company is yet to be determined.
The spray product is a nutraceutical application, separate from the ITV-1 treatment that successfully completed Phase 3 clinical trials on August 7, 2014, with the Final Report being issued in November of 2016 by Assoc. Prof. Ivaylo Elenkov, MD, Chief researcher at the Specialized Hospital for Active Treatment of Infectious and Parasite Diseases. This report and the associated clinical trials were conducted under Bulgarian Drug Administration (BDA) guidelines. With Bulgaria joining the EMA in April of 2019, the BDA can no longer issue permits for mass use for the HIV/AIDS virus. Under the Company's new business arrangement with International Medical Partners, Ltd. (IMBL), new clinical trials are being planned and scheduled with Clinical Design, a Clinical Research Organization (CRO) in Bulgaria. The Company is finalizing negotiations with a Contract Manufacturer, also located in Bulgaria, for the production of the ITV-1 Immunotherapy treatment. The new clinical trials for the Patented and licensed ITV-1 treatment under the EMA guidelines will be submitted upon completion. When the EMA permit for mass use is issued, the Company plans to pursue Federal Drug Administration (FDA) approval under the Mutual Recognition Agreement between the FDA and EMA.
As a result of the necessity to perform Clinical trials under the EMA guidelines, the agreements with IMMB BG, which were in default, have been cancelled and superseded by the new agreements with IMBL and PAW.
Harry Zhabilov, CSO, stated, "With our new partners at IMBL, the CRO and the CMO, all located in Bulgaria, and all experienced in the EMA Permitting process, the next steps in bringing our Immunotherapy Treatment for HIV/AIDS and hepatitis C viruses to a point of approval by the EMA is on the right path. The contract being negotiated with PAW is expected to produce meaningful revenue generated from our technology."
Another deal to follow before next Friday....
From today’s PR:
As a result of his efforts, we have another European transaction which we expect to consummate and report in the coming week.
OTC Filing - update 5/11....Quaterly period ending 3/31/21.
https://backend.otcmarkets.com/otcapi/company/financial-report/282365/content
Big Pharma is well aware of our capabilities, patents and with Dr Moss on the advisory board.....they know ENZC is REAL - Onwards and Upwards
As per PR 4/19:
Monoclonal Antibodies for Treatment of HIV Milestones
1st Milestone: Testing of anti-HIV Monoclonal Antibodies at University of Montana
Status: in process. Time to completion: 1 month (we are 14 days away but of course things can be delayed)
ITV-1 anti-HIV Therapeutics:
We will have a definitive timeline for the expected date of initiation and completion of clinical trials in the coming weeks.
Then we have the uplist to OTCQB which should happen very soon.
Plus this - late spring (that’s soon IMO):
Additionally, the Company has entered negotiations with Pro Wave Ad Product ("PWA"), a Bulgarian Company, to supply the raw material for PWA's Contract in India for the production of a spray modulating the immune system under U.S. Patent No. 8,309,072 owned by Zhabilov Trust. This contract is valued at more than $50 million to PWA. This is the only approved use of this technology as a nutraceutical. The FDA issued a nutraceutical number to Harry Zhabilov on October 12, 2018. The first delivery under this agreement with PWA is expected to be in late spring 2021. The value to the Company is yet to be determined.
Dr. Moss is only a part of the advisory board because he knows that CC and crew have something special....and CC could use his expertise for the launch.
Dr. Moss only joined the advisory board because he did his own DD and saw something extraordinary and wanted to be a part of a game changing company with so many different cures etc for the global population.
There’s a reason why Enzolytics is listed as DS’ Partner on their frontpage website.
VERY close Bonnie - we’ll see a PR either tomorrow or Monday - I’ll bet on that!
On Monday its two weeks since the last PR.....
For me the tweets sounds like they are VERY excited - we’ll see a PR within 1-2 days.
Have read several articles that this currency is a kind of pyramid play - can someone chip in? And if you decide to cash out - it’ll cost some pretty high fees?
Totally agree Mike - OnwardsAndUpwards
Just watched the presentation again and still have the same opinion.
ENZC holds the patents to something extraordinary - that’s a key element on the road to success.
European approval via EMA not far out (hopefully) and as he mentions it may well lead to a faster FDA approval as well.
What they are producing is not a coffee cup - its super technical and requires patience.
People investing in ENZC cannot expect a dollar price per share until they have an actual product to sell - whether its a licensing deal etc.
Once that happens it’ll easily go above $1 but time will tell. Too many are gamblers - not investors.
Do you think they’ve released around 15 PR’s in a very short and filed tons of paperwork just for fun - NO!
Also - did you really expect a partnership deal to be presented yesterday with 30 mins only to present? And without a partner and Press Release? Would never happen!
Thanks Investors of ENZC ??
#OnwardsAndUpwards
Big Pharma - would you really think that a Partnership would be informed by Enzolytics on a conference call? Any Big Pharma would release a PR at the same time as ENZC. It was never meant to happen today. But IMO it won’t be long before we’ll hear about it. Enzolytics has so many things cooking that its hard to know which one boils first.
Onwards and Upwards!
Uplisting happening by middle of May latest....
Any big pharma collaboration would never be shared on this type of conference without the pharma company being present in a joint presentation.
This week could be the best week in a long time - super excited for Wednesday’s update from CC.
When is it Wednesday? #ENZC
1st trade @ $0.0024 - avr $0.0179
Denver Scientific highlights ENZC as their partner on their front page!
http://denverscientificai.net/
Sorry if this was posted already.
The train left....did you get on it?
DR Chandra’s tweet today:
Gaurav Chandra M.D.
@drgauravchandra
·
13h
Enzolytics takes rapid strides in achieving one of the many milestones.
$ENZC #HIV #ENZC #OTCQB #COVID19 #EMA #FDA #patents ITV-1
You’re probably right - perhaps just some kind of support with the hashtags as Dr Chandra surely knows the people in the two companies. But a recent PR also mentioned soon to come partnerships. But maybe that was more meant for Genscript.
Wondering why Dr Chandra latest tweet showed hashtag# Gilead?
PR’s - No other company and I repeat - No other company (other than ENZC) have send out 13 PR’s since November 1st. Do they do it for fun? No.....this is one special company and if you are patient - then you’ll see the reward. They have the correct approach - they don’t rush things - they are working as professional as you can - making sure patents are secured and making a plan for the future - certain things are in the horizon and other things are further out. And if you’ve seen Dr Chandra’s latest tweets - then you know the company is serious. Otherwise he would never hashtag# EliLilly and Gilead!
Remember....no news = good news! #ENZC
How about this:
Enzolytics is now advancing additional complementary therapeutic platforms for treating infectious diseases, including a focus on production of anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies to treat COVID-19.
A few highlights from our website - My comment is: WAUW!!
This Enzolytics anti-HIV treatment is now being advanced through the certification stage, after which it will be available for patient therapy. ITV-1 also has also demonstrated a positive effect on different kinds of cancer due to its ability to stimulates the immune system.
The Company is in the final development of the recombinant of the parent antibody (identified as “Clone 3”) which has been shown in in vitro tests conduction in 5 international laboratories to fully neutralized over 95% of all strains and viral subtypes of HIV-1 against which it was tested.
Production of these monoclonal antibodies is being conducted in the Company’s lab at the Texas A&M University Institute for Preclinical Studies in College Station, Texas.
Presidents schedule today:
https://factba.se/biden/calendar
Is it today ENZC will be mentioned on Mad Money
No need to tweet Cramer again - he loves ENZC
Cramer of course knows that ENZC is THE future biotech company is many ways and the actitivy with PR’s etc but he is not allowed to favor any stocks or say positive things about them being in his position.
Appreciate the feedback Jack - dreaming about a very nice car.
Buyout - anyone got experience with what the PPS could be if “WE” (ENZC) is acquired by fx Gilead? Their PPS today is $63.68.
ENZC team - when are we getting another PR? LOL. Goodnight fellow fans.